Our study founded that bevacizumab can increase the level of activated CD8+ T cells in both center and periphery of the tumor by normalizing vessels, thereby transforming NSCLC into a "hot tumor" that is more susceptible to ICIs. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.